Lunit to Showcase 7 Studies at ASCO 2024, including AI Innovations in HER2 Quantification, and Multimodal Predictive Models for Immunotherapy Response

In brief

Lunit says it will present seven studies at the 2024 American Society of Clinical Oncology Annual Meeting, held in Chicago from May 31 to June 4. The research includes an AI tool for distinguishing HER2 ultra-low breast cancer cases from cases assessed as HER2-negative, and a model using chest CT scans to predict immunotherapy response in non-small cell lung cancer (NSCLC). In the HER2 analysis, the company reports that AI classified 23.6% of pathologist-assessed HER2 score 0 cases as ultra-low. Its CT model, developed using data from 1,876 NSCLC patients treated with immune checkpoint inhibitors, was associated with longer time to next treatment and overall survival among patients predicted to respond. Lunit also describes studies on melanoma immune phenotypes, tertiary lymphoid structures, early breast cancer, and treatment selection. Some research involved Stanford University School of Medicine and Northwestern University.

Key takeaways

Lunit plans seven study presentations at the ASCO 2024 Annual Meeting in Chicago.
The HER2 analysis identified ultra-low expression in 23.6% of cases assessed as score 0 by pathologists.
Lunit says its NSCLC chest CT model predicted immunotherapy response and was associated with longer treatment and survival outcomes.
Other presentations cover melanoma, tertiary lymphoid structures, early breast cancer, and treatment selection.

Lunit's ASCO 2024 presentations to highlight advances including HER2 ultra-low detection and AI-powered ICI response prediction models for NSCLC, demonstrating the impact of Lunit SCOPE suite on precision oncology

SEOUL, South Korea, May 24, 2024 -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of seven studies at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, from May 31 to June 4. Lunit will present detailed findings on several innovative studies, including the identification of HER2 ultra-low expression in breast cancer using AI-based quantification, and a deep learning-based model integrating chest CT and histopathology analysis for predicting immunotherapy response in non-small cell lung cancer (NSCLC).

In a poster presentation, Lunit’s AI-powered HER2 analyzer, Lunit SCOPE HER2, demonstrated the ability to identify HER2 ultra-low expression and differentiate it from true HER2-negative cases in breast cancer patients using continuous subcellular quantification from HER2 immunohistochemistry (IHC) images.

According to findings presented at ASCO 2022, HER2-targeted antibody-drug conjugates (ADCs) can effectively target tumor cells even in HER2-low breast cancers. This highlights the importance of accurately identifying HER2-low and HER2 ultra-low expression in breast cancer, especially for patients previously classified as HER2-negative. In response, Lunit developed an AI-based whole-slide image (WSI) analyzer for IHC-stained slides to differentiate between true HER2-negative and HER2 ultra-low cases.

The AI model evaluated over 67 million tumor cells and 119 million non-tumor cells from 401 WSIs, identifying a significant proportion of HER2 ultra-low cases among pathologist-assessed HER2 score 0 cases. This AI-powered analysis could expand and refine treatment options for patients with HER2-targeted therapies, as demonstrated by the 23.6% of HER2 score 0 cases identified as HER2 ultra-low by AI, and the 51.9% of HER2 score 1+ cases classified as HER2 low by AI, comparable to the 52.3% objective response rate to a HER2-targeted ADC observed in another clinical trial.

In another study, Lunit developed and validated an AI model that analyzes patients' chest CT images alone and in combination with pathology images to predict Immune Checkpoint Inhibitor (ICI) response in NSCLC patients. Lunit's deep learning-based chest CT prediction model, developed using data from 1,876 NSCLC patients treated with ICIs, predicted treatment response based on pre-treatment chest CT scans, along with PD-L1 status and immune phenotype.

The model demonstrated significant predictive power as an independent biomarker. Patients predicted as responders by the AI model showed significantly longer median time to the next treatment (TTNT; 7 months vs. 2.5 months) and a longer overall survival (OS; 16.5 months vs. 7.6 months) compared to patients predicted as non-responders. Combining the AI CT model with histopathologic biomarkers such as PD-L1 expression and tumor-infiltrating lymphocytes (TILs) further enhanced prediction accuracy, highlighting the complementary strengths of imaging and pathology data in improving predictive models for ICI response.

A collaborative study with Stanford University School of Medicine examined the association of immune phenotypes with outcomes after immunotherapy in metastatic melanoma, highlighting the heterogeneity of immune phenotypes across melanoma subtypes.

Another study with Northwestern University utilized AI-powered analysis of tertiary lymphoid structures (TLS) in H&E whole-slide images to predict immunotherapy response in NSCLC patients. This demonstrated AI’s potential in identifying predictive biomarkers for survival outcomes.

"At ASCO 2024, Lunit proudly presents seven groundbreaking studies that illustrate our pioneering role in AI-driven precision oncology," said Brandon Suh, CEO of Lunit. "From HER2 quantification to predictive models for immunotherapy response, our work is transforming oncology by making cancer treatment not just personalized but predictive, ensuring the best possible outcomes for patients worldwide.”

In addition to the studies above, Lunit will present three more studies at this year's ASCO, demonstrating the diverse capabilities of the Lunit SCOPE suite. The studies include comprehensive histopathomic prediction models for early breast cancer, and hypothetical test-and-control group generation for treatment selection in TPS-high NSCLC.

Visit Lunit at booth IH22 to discover how the Lunit SCOPE suite is revolutionizing oncology research and clinical practice.

Presentations at ASCO 2024 featuring Lunit SCOPE include:

If you detect any issues, problems, or errors in this press release content, kindly contact [email protected] to notify us (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). We will respond and rectify the situation in the next 8 hours.

At a glance

Company: Lunit
Ticker: KRX: 328130.KQ
Announcement: Event
Location: Seoul, South Korea

Key figures

Studies to be presented: seven
Tumor cells assessed: over 67 million
Non-tumor cells assessed: 119 million
Whole-slide images assessed: 401 WSIs
HER2 score 0 cases classified as ultra-low by AI: 23.6%
NSCLC patients in chest CT model data: 1,876

People

Brandon SuhCEO of Lunit

Products and programs

Lunit SCOPE suite
Lunit SCOPE HER2

Earlier from Lunit

Back to News Center